- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Agfa sets up dedicated DIN-PACS team
Determined to catch up with rival IBM, Agfa of Ridgefield Park, NJ, has formed a team dedicated to securing PACS contracts to military facilities under the Defense Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) project. Agfa's
Determined to catch up with rival IBM, Agfa of Ridgefield Park, NJ, has formed a team dedicated to securing PACS contracts to military facilities under the Defense Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) project. Agfa's MIL-PACS team consists of more than a dozen professionals in image networking, systems integration, product design, sales, and other areas related to DIN-PACS. The team will also include representatives from the other vendors in Agfa's DIN-PACS consortium, and will be advised by a board of military radiologists.
Agfa is trying to make up for ground lost to the consortium led by IBM, which has won $32.3 million in DIN-PACS contracts since bidding opened earlier this year (SCAN 4/1/98). Agfa, meanwhile, has yet to announce its first DIN-PACS sale publicly. DIN-PACS has a purchasing ceiling of $250 million this year.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
